Drug Profile
Estradiol transdermal - AbbVie
Alternative Names: Alora; Estran; TTI-102Latest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator Watson Laboratories
- Developer AbbVie
- Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Menopausal syndrome; Postmenopausal osteoporosis
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 15 Jan 2003 A study has been added to the adverse events and Musculoskeletal and Women's Health therapeutic trials sections
- 05 Apr 2002 Registered for Postmenopausal osteoporosis prevention in USA plus approved as a low dose 0.025 mg/day product (Transdermal)